Heterometallic Multinuclear Complexes as Anti‐Cancer Agents‐An Overview of Recent Developments

This review provides a critical assessment of the advances made in the development of heterometallic multinuclear complexes as potential chemotherapeutic agents, with the aim of providing a starting point for future investigators. The combination of the classical transition metals (Pt, Ru and Au) wi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of inorganic chemistry 2019-08, Vol.2019 (30), p.3432-3455
Main Authors: van Niekerk, Annick, Chellan, Prinessa, Mapolie, Selwyn F.
Format: Article
Language:English
Subjects:
anti‐Cancer agents
Gold
Heterometallic complexes
Inorganic chemistry
Metallodrugs
Metals
Multinuclear complexes
Pharmacology
Platinum
Structural stability
Synergistic effects
Transition metals
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review provides a critical assessment of the advances made in the development of heterometallic multinuclear complexes as potential chemotherapeutic agents, with the aim of providing a starting point for future investigators. The combination of the classical transition metals (Pt, Ru and Au) with other metal moieties has the potential to result in complexes with improved pharmacokinetic and pharmacodynamic properties. This enables selective targeting of the biological targets, which offers a possible way of circumventing the issue of drug‐resistance. This review catalogues the reported heterometallic multinuclear complexes and comments on possible synergism, stability, structure activity relationships and mechanistic studies. It was found that there remains a large scope for future research, especially concerning the combination of PtIV and CuI metals with other metals centres. Heterometallic multinuclear complexes have been found to exhibit enhanced pharmacokinetic and pharmodynamic properties with improved selective targeting for different biological targets. This provides a potential mechanism for overcoming drug resistance of known metallodrugs such as cis‐platin. The application of these types of metal complexes as anti‐cancer agents are reviewed.
ISSN:1434-1948
1099-0682
DOI:10.1002/ejic.201900375